



2 May 2023

Results of Scheme Meeting

Health House International Limited (**ASX:HHI**) (**Health House** or **the Company**) is pleased to advise that the requisite majorities of voting shares and shareholders today voted in favour of the proposed scheme of arrangement with Creso Pharma Ltd (ASX: CPH) under which CPH proposed to acquire all the shares in Health House by way of a scheme of arrangement (**Scheme**).

Results of the Scheme Meeting

In accordance with ASX Listing Rule 3.13.2 and section 251AA(2) of the Corporation Act 2001 (Cth), details of proxy votes and votes cast in respect of the resolution to approve the Scheme are set out in the attached schedule.

Next steps

The Scheme still remains subject to the approval of the Supreme Court of Western Australia (**Court**) at a second Court hearing scheduled for 9:15am (WST) on Thursday 4 May 2023 (**Second Court Hearing**) and various other conditions detailed in the Scheme Booklet.

If the Court approves the Scheme at the Second Court Hearing, Health House proposes to lodge a copy of the orders of the Court with the Australian Securities and Investments Commission on or around the date of the orders, at which time the Scheme will become legally effective (**Effective Date**).

If the Scheme is approved by the Court, Health House shares will be suspended from trading on ASX with effect from close of trading on the Effective Date and the Scheme will be implemented on or around Tuesday, 16 May 2023.

Indicative timetable

The expected key dates for the Scheme are set out below:

Event	Week ending
Second Court Hearing for approval of the Scheme	4 May 2023
Effective Date on which the Scheme comes into effect and is binding Court order lodged with ASIC and announcement to the ASX Last day of trading in Health House Shares on the ASX (with Health House Shares suspended from close of trading)	5 May 2023
Record Date for determining entitlements to Scheme Consideration	5:00 pm (AWST) on 9 May 2023
Implementation Date Payment of Scheme Consideration to be made to Scheme Shareholders	16 May 2023

All dates and times are indicative only and subject to necessary approvals from the Court and each other condition precedent to the Scheme being satisfied or waived. Health House has the right to vary the timetable detailed above subject to the approval of such variation by ASX, the Court and ASIC where required. Any changes to the above timetable will be announced to ASX and notified on the Health House website at <https://healthhouse.com.au/>

Tim Slate

Company Secretary

About Health House (www.healthhouse.com.au)

Health House International and the entities it controls (**the Group**) is an international pharmaceutical distributor specialising in, but not limited to, the distribution of medicinal cannabis products across Australasia, United Kingdom and Europe.

The Group is a fully licenced and regulated specialised importer, exporter and distributor currently distributing medicinal cannabis products from 14 producers to pharmacies, prescribers, specialist medicinal cannabis clinics and researchers across Australasia. In the UK and Germany, the Group holds all relevant licences (including GMP manufacturing), Wholesale Dealers and Controlled Drugs licences the Company supplies pharmacies, hospitals, government departments and other wholesalers with medicinal cannabis and general pharmaceutical products in the UK and Europe. The Group also integrates education of patients and healthcare professionals in the use of medicinal cannabis as a core part of its activities and is developing digital tools to enable a holistic understanding of usage.

Address

Level 3, 101 St Georges Tce
Perth WA 6000
AUSTRALIA
Tel: +61 8 6558 0886
Fax: +61 8 6316 3337
E: admin@healthhouse.com.au
W: www.healthhouse.com.au
ACN 149 197 651

Contact:

David Wheeler
David@pathwayscorporate.com.au
Tim Slate
Tim.Slate@healthhouse.com.au

SCHEME MEETING
Tuesday, 2 May, 2023

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

Resolution Voted on at the meeting			Proxy Votes (as at proxy close)				Total votes cast in the poll (where applicable)			
No	Short Description	Strike Y/N/NA	For	Against	Discretionary (open votes)	Abstain	For	Against	Abstain **	Result
1	HEALTH HOUSE INTERNATIONAL LIMITED (ASX:HHI) (HEALTH HOUSE OR THE COMPANY) HAS ENTERED INTO A SCHEME IMPLEMENTATION DEED WITH CRESO PHARMA LIMITED (CRESO)	NA	36,146,127 95.20%	1,534,751 4.04%	287,803 0.76%	0	36,433,931 95.96%	1,534,751 4.04%	0	Carried

** - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item